Screener
Altimmune ALT Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Altimmune in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Altimmune’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326190-26-000040
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Total other income (expense), net | 1,681 | 1,559 |
| Net loss before income taxes | (22,563) | (20,256) |
| Income tax expense (benefit) | — | (681) |
| Net loss | (22,563) | (19,575) |
| Other comprehensive income — unrealized loss on short-term investments | (296) | (30) |
| Comprehensive loss | $(22,859) | $(19,605) |
| Net loss per share, basic and diluted | $(0.18) | $(0.26) |
| Weighted-average common shares outstanding, basic and diluted | 124,461,818 | 75,547,746 |
Item 1. Financial Statements
FAQ
- What is Altimmune's net income?
- Altimmune (ALT) reported net income of -$22.56M in Q1 2026.
- How has Altimmune's net income changed year-over-year?
- Altimmune's net income decreased by 15.3% year-over-year, from -$19.58M to -$22.56M.
- What is the long-term trend for Altimmune's net income?
- Over 4 years (2021 to 2025), Altimmune's net income has grown at a -2.4% compound annual growth rate (CAGR), from -$97.09M to -$88.09M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Altimmune's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude